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S U M M A R Y
In most hospitals, chlorhexidine is used as skin antiseptic prior to clinical procedures, in dressings and
when bathing patients. We hereby report, for the ﬁrst time, the isolation of a clinical Klebsiella oxytoca
isolate with reduced sensitivity to chlorhexidine from a foot ulcer of a diabetic patient, which is a
common and serious complication associated with diabetes. The Minimum Inhibitory Concentration of
the K. oxytoca isolate to chlorhexidine was found to be 30 mg/L and the Minimum Bactericidal
Concentration was 60 mg/L. An increased resistance to ethidium bromide (MIC 200 mg/ L) was also
observed. Molecular tests revealed that the isolate contained blaCTXM15, blaTEM-1 and blaSHV. The other
resistant genes detected were qnrB1 and aac(60)-Ib-cr. The resistant determinants were located on a class
I integron integrase (intI1) containing qacE gene. DNA sequencing showed homology to K. oxytoca
plasmid pACM1. Identiﬁcation of K. oxytoca with reduced sensitivity to chlorhexidine raises concern
regarding dilution standards in hospitals. Adherence to the hospitals’ infection control policies should be
strictly monitored to avoid continuous low level exposure of bacteria to biocides, speciﬁcally in
developing countries.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/4.0/).
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One of the greatest perils to human health is the increasing
number of patients suffering from diabetes. Developing foot ulcers
is a common and serious complication associated with this disease
and if not treated promptly and vigorously the ulcers can lead to
osteomyelitis. In diabetic patients, up to 85% of all amputations are
preceded by an ulcer. Amputation of the lower extremities
dramatically reduces the mobility and the quality of life. Mild or
superﬁcial diabetic foot infections have been linked to aerobic
Gram-positive cocci, especially Staphylococcus aureus. Gram-neg-
ative bacilli and anaerobes have been associated with chronic
infections especially in those patients who have previously
received antibiotic therapy.1–3 The management of a diabetic
ulcer is complex, and in some cases antimicrobial therapy is
administered for months to eradicate the bacterial infection.* Corresponding author. Department of Medical Laboratory Sciences, Faculty
of Allied Health Sciences, Kuwait University, P.O. Box 31470-Sulaibekhat,
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1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-sa/4.0/).Members of the family Enterobacteriaceae, in particular the
antimicrobial resistant Klebsiella spp. are amongst the opportunis-
tic pathogens. Some of the most important causes of antibiotic
resistance in Klebsiealla are the Extended Spectrum b-lactamases
such as CTX-M-15, production of TEM-1, TEM-24, SHV-12 and the
plasmid-mediated AmpC (CMY-2).4–6 CTX-M-15 producing strains
often co-produce OXA-1 and variants of an aminoglycoside-
modifying enzyme expressed by aac(60)-Ib-cr genes that are
responsible for reduced susceptibility both to the aminoglycosides
and to some ﬂuoroquinolones.7 Fluoroquinolone (FQ) resistance in
Klebsiella spp. is usually caused by mutations in the chromosomal
type II topoisomerases, changes in the expression of efﬂux pumps
and porins and also by plasmid-mediated resistance determinants
qnr that produces the Qnr protein, which protects the quinolone
targets from inhibition.8 Moreover, strains of Klebsiella spp. have
also been shown to produce clinically important carbapenemases;
the Ambler class B metallo-b-lactamases (NDM), the class A
enzymes (KPC) and the class D oxacillinase enzymes (OXA-48).9,10
Chlorhexidine has been one of the most frequently used
biocides in hospitals for decades due to its broad spectrum of
activity, tolerability and safety record. It is commonly used as
skin antiseptic prior to clinical procedures, in dressings, hand
disinfections and when bathing patients. Previous reports haveciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
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spp in particular Klebsiella pneumonieae.11,12 One of the mecha-
nisms of reduced sensitivity to biocides is the presence of an active
efﬂux pump. Multidrug efﬂux systems export several structurally
unrelated compounds and may confer cross-resistance between
antibiotics and disinfectants, among which the small multidrug
resistance (SMR) family found in bacteria harbor qac genes that
encode small multidrug resistance (SMR) transporters and mediate
resistance to quaternary ammonium compounds (QACs).13
Although a range of methods are used for the detection of
reduced sensitivity to chlorhexidine, such as minimum inhibitory
concentration (MIC) and minimum bactericidal concentration
(MBC), there is neither a deﬁned standardized method nor
consensus on the meaning of resistance to this agent14. One of
the reasons that deﬁning the clinical relevance of reduced
sensitivity to chlorhexidine is challenging is that the concentra-
tions used clinically are often higher than those required to inhibit
the growth of the organism. However recently Morrissey et al.,15
attempted to deﬁne breakpoints for biocide resistance including
chlorhexidine. The deﬁned breakpoints are not based, as clinical
breakpoints are, on the likelihood of treatment failure, rather they
are deﬁned on the basis of the normal distribution of MICs in a
given bacterial species, or the epidemiological cut-off value
(ECOFF), which is the upper limit of the normal MICs distribution
for a given antimicrobial and a given species. The dissemination
and colonization of opportunistic pathogens with reduced
sensitivity to chlorhexidine can be alarming especially in hospitals
where biocides are readily used.
We conducted a survey of plasmid mediated quinolone
resistant (qnr-positive) Klebsiella spp. with reduced sensitivity to
chlorhexidine in diabetic patients in Kuwait from January 2010 to
December 2012. Here we report the isolation of an Extended
Spectrum b-lactamase (ESBL)-producing Klebsiella oxytoca with
reduced sensitivity to chlorhexidine from a diabetic foot infection.
2. Material and Methods
2.1. Bacterial isolates
A survey of qnr-positive Klebsiella spp. was undertaken from
January 2010 to December 2012. Three major hospitals that serve
the six governorates of Kuwait, namely Al-Ahmadi hospital, Al-
Amiri hospital and Adan hospital, were taking part in this study. All
the three hospitals are tertiary health care providers with bed
capacities of 300, 500 and 600, respectively. The average number of
specimens processed every day in each hospital varies from 500 to
700, which includes samples from out-patient and in-patient
specialists units. A database was created based on the patients’
records containing information such as age, sex, hospital, location
of care, type of specimen and date of sampling. Specimens were
processed by clinical staff members of the diagnostic microbiology
laboratories using standard protocols. All isolates were identiﬁed
at the species level based on colony morphology, biochemical
analysis and by using VITEK2 system (VITEK AMS; bioMe´rieux
VITEK Systems Inc., Hazelwood, MO, USA). The isolates were stored
in 10% skim milk and at -70 8C.
While the survey was ongoing, in 2012, K. oxytoca Y20 was
isolated from the foot ulcer (right foot) of a 48 year old type II
diabetic female patient. The patient was admitted to hospital on
12th February 2012 due to complications related to diabetes and
the wound sample was sent to the microbiology laboratory on 22nd
February 2014. The sample was processed by using conventional
microbiological techniques. The species identiﬁcation was carried
out by the API (bioMe´rieux, Marcy l’Etoile, France) and the VITEK
2 systems (Vitek AMS; bioMe´rieux Vitek Systems Inc., Hazelwood,
MO, USA). The results were analyzed according to the Clinical andLaboratory Standards Institute (CLSI) (2012) guidelines.16 The
presence of a capsule was conﬁrmed by India ink staining and
ﬁmbria typing was performed by agglutination method. There is no
record of antibiotic therapy but the patient later underwent
amputation of the limb.
2.2. Susceptibility testing
Antibiotic susceptibility tests were performed by the Kirby-
Bauer method disc diffusion test following the CLSI (2012)
recommendations.16 The antibiotics tested were ampicillin,
ampicillin/sulbactam, amoxicillin, amoxicillin/clavulanic acid,
piperacillin/tazobactam, ceftazidime, cefepime, ceftriaxone, cefa-
zolin and cefuroxime. The Minimum Inhibitory Concentration
(MIC) was determined by agar dilution method and E-test when
available for the following antibiotics: trimethoprim gentamicin,
cefotaxime, imipenem, meropenem, ciproﬂoxacin, levoﬂoxacin,
tetracycline.
2.3. Minimum Inhibitory Concentration (MIC) of chlorhexidine
The MIC for chlorhexidine digluconate (CHX; 100 mg/ml in
water; C9394; Sigma-Aldrich, St. Louis, MO, USA) was determined
using broth microdilution method. Minimum bactericidal concen-
tration (MBC) was determined by subculturing from each well
without visible bacterial growth on Mueller-Hinton agar plates.
2.4. Detection of bla genes and other resistance determinants
The presence of resistant genes (listed below) were investigated
by PCR assays as previously reported.17 PCR was conducted in a
GeneAmp 9700 (Perkin-Elmer, Illinois, USA) system using the
conditions speciﬁed for each primer; corresponding to the source
references. The resistant genes investigated were blaTEM-1, blaSHV,
blaCTX-M-like, blaNDM, blaOXA-1, qnrA, qnrB, qnrS, aac(6
0)-Ib Ib-cr, gyrA,
parC, gyrB, parE, intI1, intI2, blaKPC, blaVIM, blaIMP, blaOXA-48, and
ampC. The detection of blaPER-like, blaGES-like and blaVEB-like was
performed by PCR according to Opazo et al.18 PCR was also used to
detect qac and smr genes.19
Ampliﬁed PCR products were puriﬁed with Qiagen puriﬁcation
kit (Qiagen, Limburg Netherlands) according to the manufacturer’s
instructions and both strands were sequenced by automated
ABI3100 DNA sequencer (Applied Biosystems, Foster City, CA,
USA). The BLAST program of the National Centre for Biotechnology
Information (http://www.ncbi.nlm.nih.gov) was used to search
and compare databases for similar nucleotide sequences.
2.5. Demonstration of efﬂux pump activity mediating multi-drug
resistance by ethidium bromide agar method
The evaluation of efﬂux systems by the retention of the
ﬂuorescent dye ethidium bromide (EtBr) was performed according
to Martins et al.20,21 This technique employs EtBr as the pump
substrate that allows the veriﬁcation of the existence of an
overexpressed efﬂux system relative to the intrinsic efﬂux
activities of a wild-type strain; in this case E. coli NCTC
10418 was used as the reference strain. The swabbed EtBr-agar
plates were incubated at 378C for 16 h and examined under a UV
transilluminator. The minimum concentration of EtBr that
produced ﬂuorescence of the bacterial mass was recorded.
2.6. Pulsed-Field Gel Electrophoresis (PFGE)
PFGE was performed by using the restriction enzyme XbaI,22
with a run time of 20 h and switch times of 5 to 50 and 5 to 35 s at
14 8C and 6 V/cm (CHEF-DR II System; Bio-Rad, Hercules, CA, USA).
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version 7.1 (Applied Maths, Sint-Martens-Latem, Belgium).
2.7. Plasmid extraction and detection
Plasmids were extracted (Promega, Madison, WI, USA) and
characterized by PCR as described previously.23 Larger plasmids
were detected by PFGE technique. A single block was incubated at
55 8C for 1 hour with 1 unit of S1 nuclease (New England Biolabs,
Ipswich, MA, USA) in Zinc Buffer (200 ml of 50 mM NaCl, 30 mM
sodium acetate and 5 mM ZnSO4). Electrophoresis was performed
at 6 V, 5-50s for 20 hours.24
3. Results
A total of 174 Klebsiella spp. were isolated from diabetic
patients. Twenty eight out of the 174 (16%) contained a plasmid-
mediated quinolone resistance gene (qnr): 27 K. pneumoniae and
1 K. oxytoca. None of the K. pneumonia showed reduced sensitivity
to chlorhexidine.
3.1. K. oxytoca
API, VITEK2, India ink staining and ﬁmbria typing tests
conﬁrmed that K. oxytoca Y-20 was a capsulated, type 1 ﬁmbriae
producing isolate.
3.2. Susceptibility testing for K. oxytoca
The result of antibiotic sensitivity testing by the VITEK system
and the disc diffusion tests showed that Y-20 was resistant to
ampicillin, ampicillin/sulbactam, amoxicillin, ceftazidime, cefe-
pime, ceftriaxone, cefazolin and cefuroxime. In contrast it was
sensitive to piperacillin/tazobactam and amoxicillin/clavulanic
acid. The MIC results are shown in Table 1.
3.3. Identiﬁcation of resistance genes in K. oxytoca
The resistant genes detected were blaCTX-M-15, blaTEM-1, blaSHV,
aac(60)-Ib-cr, blaOXA-1 on a class I integron integrase (intI1) gene
(Sequence ID: gbjFJ663011.1j) containing qacE gene (Sequence ID:
gbjCP003684.1j) which encodes quaternary ammonium com-
pound-resistance protein QacE. Y-20 also contained qnrB1 gene
(Sequence ID: gbjAFF27560.1j). However we did not detect any
other resistance determinants.Table 1
The MIC (mg/L) results of the antimicrobial agents tested against K. oxytoca
isolateY-20.
Antimicrobial Agent Breakpoint mg/L MIC mg/L
Amoxi/clavulanic acid 32/16 16/8
Amp/sulbactam 32/16 64/32
Ampicillin 32 128
Cefotaxime 4 64
Cefotaxime / clavulanic acid 32/16 0.032
Piperacillin / tazobactam 128/4 8/1
Ceftazidime 16 64
Ceftriaxone 4 128
Levoﬂoxacin 8 8
Ciproﬂoxacin 4 4
Gentamicin 16 >256
Imipenem 2 0.32
Meropenem 2 0.32
Trimethoprim 16 >32
Tetracycline 16 323.4. Identiﬁcation of efﬂux pump
K. pneumonieae isolates had an MIC range of 1-30 mg/L for
chlorhexidine. The MIC of Y20 to Chlorhexidine was 60 mg/L and
the MBC was 120 mg/L. An increased resistance to ethidium
bromide (MIC 200 mg/l) was also observed. Nevertheless, Y-20 did
not show the capacity to retain ethidium bromide according to the
cart-wheel experiment.
3.5. Plasmid Analysis
In K. oxytoca (Y-20) Two large plasmids with molecular weights
of around 140 kb and 190 kb were detected with PFGE after
digestion with S1 nuclease (Figure 1). Sequencing the PCR products
from the 140 kb plasmid revealed 99% homology to K. oxytoca
plasmid pACM1 (Sequence ID: gbjU90945.1jKOU90945), contain-
ing quaternary ammonium compound transporter protein (qacE
delta 1) gene, partial cds genes: 300-0-adenyltransferase (ant(300)-Ia),
3-N-aminoglycoside acetyltransferase (aac(3)-Ia) and 60-N-amino-
glycoside acetyltransferase (aac(60)-Ib) genes, and DNA integrase
(intI1) gene.
4. Discussion
Here we report for the ﬁrst time the identiﬁcation of a K. oxytoca
isolate from a diabetic foot infection with reduced sensitivity to
chlorhexidine.
K. oxytoca usually colonizes the soft tissues of the respiratory
and the gastrointestinal tracts in patients who have severe
underlying diseases,25 and is rarely associated with diabetic
ulcers. Isolating K. oxytoca has previously been reported from a
liver abscess of a diabetic patient which was originated from anFigure 1. Agarose gel showing S1 nuclease digest of K. oxytoca Y-20. PFGE-based
sizing of large plasmids suggests Y-20 contains two large plasmids of about 140 kb
and 190 kb. Lane 1: PFGE of Y-20 digested with XbaI. Lane 2: PFGE Lambda marker
used as the reference. The molecular weight of the bands from the bottom to the top
is 48.5 kb, 97 kb, 145.5 kb, 194 kb, 242.5 kb, 291 kb, 339.5 kb, 388 kb, and 436.5 kb
respectively. Lane 3: S1 nuclease digest of K. oxytoca Y-20.
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undiagnosed type 2 diabetes.27
The pathogenic potential of K. oxytoca is not limited to causing
intestinal infection and antibiotic-associated hemorrhagic colitis28
and its potential as an opportunistic pathogen in patients with
diabetic foot ulcers should be further explored. In our study the
severity of the diabetic foot infection increased with the presence
of class 1 integrons producing ESBL enzymes and low sensitivity to
chlorhexidine. The key ﬁnding in this study was the presence of the
qacE gene in K. oxytoca located in the 30-CS of class 1 integrons. qacE
gene belongs to the SMR family29 conferring efﬂux-mediated
resistance to QACs. Several members of the SMR family have been
shown to export a range of toxins, including ethidium bromide and
QACs, through coupling with proton inﬂux.30
Chlorhexidine is probably one of the most widely used biocides,
not only in hand washing and oral products but also as a
disinfectant and preservative. Nearly four decades ago Casewell
and Phillips31 showed that the rate of transfer of Klebsiella was
signiﬁcantly reduced after washing hands with chlorhexidine.
Thirty years later in a neonatal and pediatric intensive care unit,
the source of a sepsis outbreak was K. oxytoca with reduced
sensitivity to biocides, which was isolated from contaminated
0.25% formaldehyde based disinfectant solution.32
Continuous assessment of the infection control and preventive
measures implemented in hospitals is crucial to avoid the
emergence of ESBL producing Enterobactericeae with reduced
sensitivity to biocides. In particular failure to adhere to standard
control procedures such as hand hygiene can increase the
possibility of the dissemination of resistant isolates. In most cases
the concentrations of chlorhexidine used are higher than the doses
required to inhibit the growth of nosocomial organisms. But as
breakpoints have not yet been established by the CLSI, it is difﬁcult
to interpret what chlorhexidine resistance is actually deﬁned as.
In conclusion, this is the ﬁrst report of K. oxytoca with reduced
sensitivity to chlorhexidine that contains qacE gene in a diabetic
ulcer. To avoid continuous low level exposure of K. oxytoca to
biocides which may result in emerging strains with reduced
sensitivity to these agents, dilution standards in hospitals
speciﬁcally in developing countries and the hospital’s adherence
to infection control policies should be strictly monitored.
Administering preventive measures by using the correct dose of
biocides is essential.
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